Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fleury S.A. (FLRY3.SA)
São Paulo, SP, BR
Fleury S.A., a Brazilian healthcare provider, along with its subsidiaries, delivers a broad spectrum of medical services. These offerings span diagnostics, various treatments, clinical analysis, health management, general medical care, orthopedics, and ophthalmology. The company organizes its operations into three primary segments: Diagnostic Medicine, Integrated Medicine, and Dental. Its service portfolio includes laboratory and imaging examinations, comprehensive diagnostic information, health check-ups, specialized reference laboratory functions, genomic testing, day clinic facilities, infusion centers, and dental imaging and radiology. Additionally, Fleury provides Saúde I, a digital health platform that facilitates teleconsultations, remote medical advice, online diagnostic exams, and virtual procedures. It further extends its services to corporate clients with tailored solutions, offers in-person primary care, and supports medical professionals through digital office tools and ongoing medical education. Established in 1926 and headquartered in São Paulo, Brazil, the company operates an extensive network comprising 284 outpatient service centers and 31 hospital-based units, many of which are known under brands like Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, Diagmax, IRN / CPC, Diagnosis a+, a+BA, Pretti, and Bioclinic.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.45% | -2.10% | -3.43% | -5.77% | +1.24% | +10.18% | +29.17% | +15.72% | -17.68% | +106.57% | +234.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+7.9% Q1'26: +10.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-0.9% Q1'26: +12.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+8.5% Q1'26: +9.2% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+14.8% ★ Q1'26: +19.2% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+11.8% ★ Q1'26: +15.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.1% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.48× Q1'26: 2.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 6 EPS Ana. |
Dec 2027 11 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.89B
est: 1.88B (+0.5%)
|
2.10B
est: 2.10B (-0.2%)
|
2.38B
est: 2.39B (-0.5%)
|
2.66B
est: 2.66B (+0.3%)
|
2.91B
est: 2.90B (+0.1%)
|
2.97B
est: 2.88B (+3.0%)
|
3.87B
est: 3.88B (-0.1%)
|
4.46B
est: 4.34B (+2.8%)
|
6.47B
est: 7.46B (-13.2%)
|
7.68B
est: 7.69B (0.0%)
|
8.29B
est: 8.27B (+0.3%)
|
9.04B
9.02B – 9.05B
+9.3% YoY
|
9.66B
9.10B – 10.12B
+6.9% YoY
|
10.26B
10.22B – 10.29B
+6.2% YoY
|
9.60B
9.31B – 9.84B
-6.4% YoY
|
9.96B
9.66B – 10.21B
+3.7% YoY
|
| EBITDA |
431.44M
est: 521.92M (-17.3%)
|
574.79M
est: 581.73M (-1.2%)
|
655.04M
est: 662.90M (-1.2%)
|
723.84M
est: 735.82M (-1.6%)
|
896.85M
est: 803.82M (+11.6%)
|
846.27M
est: 798.49M (+6.0%)
|
1.08B
est: 1.07B (+1.0%)
|
1.27B
est: 1.20B (+5.8%)
|
1.69B
est: 2.02B (-16.5%)
|
2.10B
est: 2.08B (+1.0%)
|
2.12B
est: 2.24B (-5.3%)
|
2.45B
2.45B – 2.45B
+9.3% YoY
|
2.62B
2.47B – 2.74B
+6.9% YoY
|
2.78B
2.77B – 2.79B
+6.2% YoY
|
2.60B
2.52B – 2.67B
-6.4% YoY
|
2.70B
2.62B – 2.77B
+3.7% YoY
|
| EBIT |
304.73M
est: 322.47M (-5.5%)
|
429.43M
est: 359.43M (+19.5%)
|
526.03M
est: 409.58M (+28.4%)
|
532.33M
est: 454.64M (+17.1%)
|
578.77M
est: 496.65M (+16.5%)
|
487.80M
est: 493.36M (-1.1%)
|
689.83M
est: 663.17M (+4.0%)
|
818.55M
est: 742.52M (+10.2%)
|
1.01B
est: 1.25B (-19.0%)
|
1.32B
est: 1.29B (+2.2%)
|
1.22B
est: 1.39B (-11.8%)
|
1.52B
1.51B – 1.52B
+9.3% YoY
|
1.62B
1.53B – 1.70B
+6.9% YoY
|
1.72B
1.72B – 1.73B
+6.2% YoY
|
1.61B
1.56B – 1.65B
-6.4% YoY
|
1.67B
1.62B – 1.71B
+3.7% YoY
|
| Net Income |
107.34M
est: 197.90M (-45.8%)
|
228.75M
est: 367.91M (-37.8%)
|
320.62M
est: 512.60M (-37.5%)
|
331.59M
est: 556.01M (-40.4%)
|
312.32M
est: 552.06M (-43.4%)
|
256.96M
est: 355.78M (-27.8%)
|
349.93M
est: 593.87M (-41.1%)
|
307.91M
est: 488.76M (-37.0%)
|
423.76M
est: 597.02M (-29.0%)
|
616.17M
est: 633.68M (-2.8%)
|
612.83M
est: 596.73M (+2.7%)
|
673.97M
671.61M – 693.82M
+12.9% YoY
|
777.14M
730.77M – 850.97M
+15.3% YoY
|
889.19M
833.85M – 986.45M
+14.4% YoY
|
920.96M
884.54M – 950.85M
+3.6% YoY
|
975.46M
936.88M – 1.01B
+5.9% YoY
|
| SGA |
66.32M
est: 47.33M (+40.1%)
|
76.98M
est: 52.75M (+45.9%)
|
256.54M
est: 60.11M (+326.8%)
|
67.79M
est: 66.72M (+1.6%)
|
51.28M
est: 72.89M (-29.6%)
|
55.05M
est: 72.41M (-24.0%)
|
72.44M
est: 97.33M (-25.6%)
|
114.95M
est: 108.97M (+5.5%)
|
190.74M
est: 203.60M (-6.3%)
|
254.19M
est: 209.86M (+21.1%)
|
244.59M
est: 225.78M (+8.3%)
|
246.74M
246.33M – 247.15M
+9.3% YoY
|
263.79M
248.58M – 276.19M
+6.9% YoY
|
280.05M
279.16M – 280.94M
+6.2% YoY
|
262.11M
254.14M – 268.66M
-6.4% YoY
|
271.90M
263.63M – 278.68M
+3.7% YoY
|
| EPS |
0.33
est: 0.36 (-9.2%)
|
0.69
est: 0.68 (+2.1%)
|
0.96
est: 0.94 (+1.9%)
|
0.99
est: 1.02 (-3.1%)
|
0.93
est: 1.01 (-8.3%)
|
0.76
est: 0.65 (+16.3%)
|
1.05
est: 1.09 (-3.8%)
|
0.91
est: 0.90 (+1.3%)
|
0.87
est: 1.09 (-20.5%)
|
1.13
est: 1.17 (-3.2%)
|
1.12
est: 1.08 (+3.5%)
|
1.25
1.23 – 1.27
+15.9% YoY
|
1.45
1.34 – 1.56
+16.0% YoY
|
1.63
1.53 – 1.81
+12.0% YoY
|
1.69
1.62 – 1.74
+3.7% YoY
|
1.79
1.72 – 1.85
+5.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Angelica Dente de Menezes | Secretary | — | — |
| Edgar Gil Rizzatti | Medical, Technical & Process Executive Director and Member of Executive Board | — | male |
| Jeane Mike Tsutsui | Chief Executive Officer & President of Executive Board | — | female |
| Jose Antonio de Almeida Filippo | CFO & Member of Executive Board | — | male |
| Patricia Yumi Maeda Bertoncello | Executive Director of Service Units & Member of Executive Board | — | female |
| Renato de Oliveira Braun | Investor Relations Director | — | male |
| Roberto Santoro Meirelles | L2L & Operations Support Officer and Member of Executive Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FLRY3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
